CA
NZ
UK
AU
IND
US
Baxter International Inc. has reported strong second-quarter results, achieving sales of $2.96 billion, reflecting a 5% year-over-year increase. This growth was consistent across all segments, highlighting the company's diverse product offerings and market presence. The quarterly dividend remains unchanged at $0.01 per share, a …
The broader implications of this loss contribute to a year-to-date stock decline of 40%, as investor confidence wanes against a backdrop of high operational costs and ongoing clinical expenses.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has announced substantial financial results for the second quarter of 2026, marking a notable revenue increase that investors should take into account. Total revenues reached $44.7 million, a sharp rise from $12.5 million reported in Q2 2025, driven by …
The lease is effective from September 1, 2026, and extends until September 30, 2029. This move could bolster the company's capacity to innovate and respond to market demands, although it comes at a time when Aldeyra is facing notable challenges reflected in its steep …
Alignment Healthcare (NASDAQ: ALHC) delivered impressive financial results for the second quarter, revealing a total revenue of $1.34 billion, marking a strong increase of 31.6% compared to the prior year. The earnings per share stood at $0.17, surpassing a consensus estimate of $0.13, reflecting …
Alnylam Pharmaceuticals, Inc. raised its full-year revenue guidance to $4.5 billion, reflecting a 7% increase. The company also reported $1.17 billion in Q2 product revenues, indicating strong demand for its TTR therapies and advancing clinical pipeline.Key HighlightsAlnylam raised its full-year 2026 revenue guidance to …
AnaptysBio Inc. (NASDAQ: ANAB) is embroiled in a significant legal battle as it challenges Tesaro, Inc. following allegations of a material breach of their collaboration agreement. The company filed its Verified Complaint on November 20, 2025, in Delaware Court of Chancery, asserting that not …
Anavex Life Sciences Corp. (NASDAQ: AVXL) delivered a second‑quarter loss of $5.3 million, translating to $0.06 per share, a marked improvement from the $11.2 million loss a year earlier. The company also beat consensus earnings expectations. Cash balances climbed to $127.4 million from $102.6 …
Senseonics (NYSEAMERICAN:SENS) heads into its second-quarter earnings report, scheduled for August 6, 2026, with fresh momentum and fresh scrutiny. The near-term catalyst is the first full year in which the company controls its own U.S. commercial destiny. On January 1, 2026, Senseonics ended its …
Femasys (NASDAQ:FEMY) spent the spring stacking regulatory and commercial milestones on top of a fight to keep its Nasdaq listing. On May 13, 2026, the Suwanee, Georgia device maker said its FemHSG catheter had received a European CE Mark, clearing the way for in-office …
Please wait processing your request...